Skip to content

Randomized Controlled Trial Of Resveretrol-Copper Or Sodium-Copper-Chlorophyllin Vs Standard Treatment In Mild Covid-19 infection with Cancer Patients.

A Phase-III, Open Label, Randomized Controlled Trial of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment in Cancer patients with SARS-CoV-2 Infection who are Asymptomatic Or Mildly Symptomatic for Covid 19.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026515
Enrollment
300
Registered
2020-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and non-pregnant female cancer patients 18 years of age or older. 2. Positive reverse-transcriptaseâ??polymerase polymerase chain-reaction (RT-PCR) in a diagnostic specimen 3. Either asymptomatic or have only mild symptoms ((cough and/or fever and/or sore throat and/or other upper respiratory symptoms) at the time of study inclusion 4.Oxygen saturation of >94% while breathing ambient air, if this is measured 5.Either normal levels of haematological, liver and renal functions, and electrolytes OR no worse than Grade 1 (CTCAE Version 5.0) abnormalities in any of these parameters. 6. Patients with high blood sugar or glycosylated haemoglobin, of any degree will be eligible 7. Arterial blood gas, if done, should have normal values of pH, PO2, PCO2 and bicarbonate level.

Exclusion criteria

Exclusion criteria: 1.Cancer diagnosis not proven 2. Have pneumonia confirmed by chest imaging, 3. Have oxygen saturation (Sao2) of 94% or less while they were breathing ambient air 4.Have any Grade 2 or worse laboratory abnormality, including haematological, renal, liver, electrolyes.

Design outcomes

Primary

MeasureTime frame
the proportion of patients who suffer clinical deterioration OR viral persistence at Day 10 from the date of randomization (excluding the date of randomization).Timepoint: 10 Days

Secondary

MeasureTime frame
1.All-cause mortality at 28 days after randomization (28-day mortality) 2.Overall Survival times in days (with any-cause death constituting an event) 3.The proportion of patients with virological positivity. 4. Translational, including biomarker-related, research in banked bio-specimens.Timepoint: 1.Day 28 2.Day 28 3.Day 10 4.Day 0,5,10,Discharge

Countries

India

Contacts

Public ContactVIKRAM GOTA

ACTREC, Tata Memorial Centre

vikramgota@gmail.com7715019117

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026